Valuation Eurofins Scientific SE London S.E.
Stocks
0MV5
FR0014000MR3
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.70 EUR | +1.46% |
|
+3.14% | +11.89% |
| 07-23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
Company Valuation: Eurofins Scientific SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 20,893 | 12,900 | 11,336 | 9,273 | 11,036 | 12,096 | - | - |
| Change | - | -38.26% | -12.13% | -18.2% | 19.02% | 9.61% | - | - |
| Enterprise Value (EV) 1 | 23,132 | 15,739 | 14,041 | 12,269 | 14,677 | 15,445 | 15,109 | 14,863 |
| Change | - | -31.96% | -10.79% | -12.62% | 19.63% | 5.23% | -2.18% | -1.63% |
| P/E | 27.8x | 22.2x | 45.4x | 26.9x | 28x | 23.2x | 18.3x | 15.4x |
| PBR | 4.49x | 2.7x | 2.24x | 1.73x | 2.56x | 2.6x | 2.36x | 2.18x |
| PEG | - | -1x | -0.8x | 0.7x | 1.3x | 0.7x | 0.7x | 0.8x |
| Capitalization / Revenue | 3.11x | 1.92x | 1.74x | 1.33x | 1.51x | 1.59x | 1.51x | 1.41x |
| EV / Revenue | 3.44x | 2.34x | 2.16x | 1.77x | 2.01x | 2.03x | 1.89x | 1.74x |
| EV / EBITDA | 12.2x | 10.4x | 10.3x | 7.91x | 8.94x | 8.81x | 7.95x | 7.17x |
| EV / EBIT | 15.7x | 15.2x | 16.7x | 12.1x | 13.6x | 13.5x | 11.9x | 10.6x |
| EV / FCF | 22.8x | 23.2x | 29.6x | 15.3x | 16.7x | 17.7x | 15.9x | 14.3x |
| FCF Yield | 4.39% | 4.3% | 3.38% | 6.53% | 5.97% | 5.64% | 6.3% | 7.02% |
| Dividend per Share 2 | 1 | 1 | 0.5 | 0.5 | 0.72 | 0.808 | 0.9164 | 0.9723 |
| Rate of return | 0.92% | 1.49% | 0.85% | 1.01% | 1.15% | 1.16% | 1.32% | 1.4% |
| EPS 2 | 3.91 | 3.02 | 1.3 | 1.83 | 2.23 | 3.006 | 3.802 | 4.512 |
| Distribution rate | 25.6% | 33.1% | 38.5% | 27.3% | 32.3% | 26.9% | 24.1% | 21.5% |
| Net sales 1 | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 | 7,592 | 8,013 | 8,553 |
| EBITDA 1 | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 | 1,753 | 1,901 | 2,072 |
| EBIT 1 | 1,473 | 1,037 | 842 | 1,017 | 1,079 | 1,144 | 1,264 | 1,405 |
| Net income 1 | 783 | 606 | 310 | 406 | 475 | 532.2 | 661 | 819 |
| Net Debt 1 | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 | 3,349 | 3,013 | 2,766 |
| Reference price 2 | 108.80 | 67.06 | 58.98 | 49.31 | 62.40 | 69.68 | 69.68 | 69.68 |
| Nbr of stocks (in thousands) | 192,035 | 192,365 | 192,194 | 188,049 | 176,864 | 173,599 | - | - |
| Announcement Date | 2/22/22 | 3/1/23 | 2/27/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.67x | 5.84x | 17.38x | 0.98% | 48B | |
| -24.15x | 363.29x | -22.19x | -.--% | 41.13B | |
| 29.32x | 2.95x | 12.73x | -.--% | 37.56B | |
| 47.98x | 4.87x | 31.77x | -.--% | 35.91B | |
| 28.27x | 8.18x | 20.56x | 0.41% | 29.86B | |
| 32.7x | 5.35x | 24.3x | -.--% | 16.05B | |
| 26.61x | 1.78x | 10.95x | -.--% | 12.1B | |
| 38.19x | 3.4x | 13.22x | -.--% | 11.28B | |
| Average | 26.45x | 49.46x | 13.59x | 0.17% | 28.99B | |
| Weighted average by Cap. | 23.81x | 68.56x | 12.19x | 0.26% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ERF Stock
- 0MV5 Stock
- Valuation Eurofins Scientific SE
Select your edition
All financial news and data tailored to specific country editions
